期刊
LANCET
卷 386, 期 10003, 页码 1588-1598出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(15)00418-3
关键词
-
资金
- Servier
- Takeda
- Medtronic
- Relypsa
- Bayer
- AbbVie
- Amgen
- Shire
- Fresenius Medical Care
- Nipro
- Baxter
- GlaxoSmithKline
- MSD
- Eli Lilly
- Sanofi- Genzyme as part of the CKD-REIN study Public-Private Partnership
Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant hypertension in chronic kidney disease stages 3-5 (ie, patients with an estimated glomerular filtration rate below 60 mL/min per 1.73 m(2) and not on dialysis), in terms of worldwide epidemiology, outcomes, causes and pathophysiology, evidence-based treatment, and a call for action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据